Continuous Individualized Risk Index

<p>Continuous Individualized Risk Index (CIRI) (initialism pronounced /ˈsɪri/) is to a set of probabilistic risk models utilizing <a href="/facts/Bayesian_probability/Cvn7WWfG">Bayesian statistics</a> for integrating diverse cancer <a href="/facts/Biomarker/nk2LgXtq">biomarkers</a> over time to produce a unified prediction of outcome risk, as originally described by Kurtz, Esfahani, et al. (2019) from Ash Alizadeh's laboratory at Stanford. Inspired by in game <a href="/facts/Win_probability/z1JAD3H6">win probability</a> models for predicting winners in sports and political elections, CIRI incorporates serial information obtained throughout a given patient's course to estimate a personalized estimate of various cancer-related risks over time. CIRI models have been developed available for various cancer types, including <a href="/facts/Breast_cancer/6hME580v">breast cancer</a> (BRCA), <a href="/facts/Diffuse_large_B-cell_lymphoma/7FSQMurk">diffuse large B-cell lymphoma</a> (DLBCL), and <a href="/facts/Chronic_lymphocytic_leukemia/jbaDruD9">chronic lymphocytic leukemia</a> (CLL).The serial information integrated can be diverse, including choice of therapy and the associated responses observed, whether using <a href="/facts/Liquid_biopsies/1HMoPqmH">liquid biopsies</a> or radiological studies, pathological and other dynamic measurements.
</p>

Continuous Individualized Risk Index open-in-new

Continuous Individualized Risk Index